Form 4: Century Therapeutics CFO Receives Stock Options and Restricted Stock Units

Morgan Conn, CFO of Century Therapeutics, Inc., reports the acquisition of stock options and restricted stock units.

Summary

• On October 14, 2024, Morgan Conn, the Chief Financial Officer of Century Therapeutics, Inc., acquired 60,148 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest 25% on October 14, 2025, and the remaining 75% vest quarterly over the following three years, contingent upon continued service.
• Conn also acquired options to purchase 360,890 shares of common stock at an exercise price of $1.48.
• These options vest 25% on October 14, 2025, with the remaining 75% vesting in 36 equal monthly installments, also subject to continued service.
• Following these transactions, Conn directly owns 60,148 shares of common stock and options to purchase 360,890 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of equity-based compensation is generally viewed favorably as it aligns management's interests with shareholders. There are no explicit negative indicators.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Stock options and RSU grants are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry typically include a mix of salary, bonus, stock options, and restricted stock units.
• The vesting schedules for the RSUs and stock options are fairly standard, with initial vesting occurring after one year and subsequent vesting over a three-year period.
• Comparable companies in the biotech sector, such as CRISPR Therapeutics and Editas Medicine, also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates